When a CMC team detects an unexpected glycan motif in a drug substance lot, the question is never purely analytical. The glycosylation profile of a biologic directly shapes how the immune system perceives the molecule: some glycan structures are recognized as non-self, triggering anti-drug antibodies (ADA) that can compromise efficacy and patient safety. For a European biotech preparing a preclinical package, glycan characterization is therefore not a descriptive annex — it is a core input of immunogenicity risk assessment.
Direct answer: Glycosylation influences the immunogenicity of biologics because glycan structures alter the antigenic surface of the molecule and can expose non-human epitopes — such as Neu5Gc or alpha-Gal — that the human immune system recognizes as foreign, inducing anti-drug antibodies. The same parameter works in reverse as a lever: glycoengineering can reduce immunogenicity or tune effector functions. Early, rigorous glycan characterization supported by reliable reference standards is what makes the resulting risk assessment defensible before regulators.
This article maps the glycan motifs that raise the immunogenicity flag, links them to the expectations of ICH, EMA and FDA, and sequences a practical risk workflow. The thread throughout: glycosylation is both a risk to document and a design asset to exploit — provided the analytical foundations are solid.
Glycosylation shapes immunogenicity: the core connection
The glycan structures attached to a biologic modify its antigenic surface. When those structures include motifs absent from the human glycome — xenoantigens — the immune system can mount a specific antibody response against them. A French doctoral work defended at Oniris (Université Bretagne Loire) documents this mechanism concretely: administration of a therapeutic protein of animal origin, rabbit anti-thymocyte serum, induces anti-Neu5Gc and anti-alpha-1,3-Gal antibody responses in humans, two xenoantigens absent from the human glycome.
The mechanism operates at three levels. First, new glycan epitopes can be directly immunogenic, as the Neu5Gc and alpha-Gal examples show. Second, altered glycosylation can affect protein folding and expose buried peptide regions, creating neo-epitopes. Third, glycan heterogeneity drives aggregation and product variability, both recognized contributors to unwanted immune responses.
A French cohort study strengthens the human evidence base: the NutriNet-Santé study on Neu5Gc, published in BMC Medicine in 2020, measured daily Neu5Gc intake in 19,621 adults and quantified anti-Neu5Gc antibodies by ELISA and glycan microarrays in 120 individuals — confirming that humans do mount immune recognition against this xenoantigen, in a dietary context. The transferability to therapeutic proteins remains contextual: the study was not conducted on biopharmaceutical products, but the immunological recognition of the motif itself is established.
One distinction frames the rest of this article. Glycosylation is a double-edged parameter: certain motifs constitute a risk signal to document, while deliberate glycoengineering — reshaping the glycan profile by design — is a proven lever to reduce immunogenicity or modulate effector functions. Treating the glycosylation profile as a mere descriptive attribute is the recurring mistake this article corrects.
Which glycan patterns raise the immunogenicity flag?
Three families of glycan features deserve systematic attention in an immunogenicity risk assessment: non-human motifs, highly mannosylated structures, and Fc glycosylation patterns that shape effector functions.
Non-human motifs come first, because their immunological status is the best documented. Neu5Gc (N-glycolylneuraminic acid) and alpha-Gal (alpha-1,3-galactose) are absent from the human glycome; humans naturally carry antibodies against them. The Oniris thesis cited above shows that a biomedicament of animal origin induces anti-Neu5Gc and anti-alpha-1,3-Gal responses — a direct, human-documented link between a glycan motif and an antibody response. For a mAb produced on a non-human cell line, detecting either motif means detecting a potential ADA trigger. The typical CMC scenario: an unexpected Neu5Gc signal appears in a lot produced on a non-human line. The question immediately shifts from « is the peak real? » to « can we confirm, quantify and defend it? »
Highly mannosylated glycans form the second category. Elevated mannose content is primarily a quality signal — an indicator of process consistency and cell-line behavior — and its direct immunogenic contribution is less firmly established in the literature than for Neu5Gc or alpha-Gal. The prudent reading: monitor it as a critical quality attribute, and treat any shift as a signal requiring investigation rather than a proven immunogenic trigger.
Fc glycosylation and effector functions constitute the third, most nuanced case. The glycosylation profile and modifications to the Fc fragment are among the factors that can influence the immunogenicity of a biological medicine compared with its reference product. Core fucosylation provides a well-known example: reducing fucose levels can increase antibody-dependent cellular cytotoxicity (ADCC), which may be desirable in certain oncology applications, while also modifying the molecule’s interactions with immune receptors. This distinction is important when assessing the characteristics of a biological medicine: afucosylation can represent a deliberate glycoengineering strategy designed to enhance a specific biological function rather than a manufacturing defect. The significance of the modification therefore depends on its intended purpose and biological context.
The table below synthesizes these motifs for quick triage.
| Glycan feature | Typical origin | Immunological reading | Priority in risk assessment |
|---|---|---|---|
| Neu5Gc | Non-human cell lines, animal-derived materials | Xenoantigen; human immune recognition documented (anti-Neu5Gc antibodies) | High — confirm, quantify, document |
| alpha-Gal (alpha-1,3-Gal) | Non-human cell lines expressing alpha-1,3-galactosyltransferase | Xenoantigen; anti-alpha-Gal responses documented in humans | High — confirm, quantify, document |
| High-mannose glycans | Process and cell-line dependent | Mainly a quality/consistency signal; direct immunogenicity less established | Medium — monitor as CQA |
| Fc fucosylation level | Cell line and culture conditions | Modulates ADCC; can be a glycoengineering asset or a comparability concern | Context-dependent — define intent early |
One caveat applies to the whole table: published thresholds or « acceptable » levels of Neu5Gc or alpha-Gal in mAb lots are not consolidated in a single public reference. The defensible approach is quantitative characterization against reference standards, followed by a documented risk rationale — not a rule-of-thumb percentage.
From glycan analysis to regulatory expectations
Two ICH guidelines frame the exercise. ICH Q6B, the guideline on test procedures and acceptance criteria for biotechnological/biological products, establishes glycosylation profiling as part of the characterization expected for glycoprotein drug substances. ICH S6(R1), the preclinical safety evaluation guideline, addresses the immunogenicity evaluation of biotechnology-derived pharmaceuticals and expects sponsors to identify product-related factors that could drive an immune response. Together, they define the perimeter: characterize the glycan profile, identify species-specific or atypical motifs, and justify their potential contribution to immunogenicity.
At the national level, the ANSM biosimilars report provides a useful transposition: the glycosylation profile and Fc modifications are among the parameters that can shift immunogenicity, and the marketing authorization pathway for a biosimilar does not differ from that of a new molecule — meaning the same rigor of glycan characterization is expected. EMA and FDA review immunogenicity risk assessments with this logic: a sponsor who documents which motifs are present, at what levels, with what analytical confidence, and what the clinical consequence could be, presents a defensible dossier. A sponsor who reports a glycan profile without quantified confirmation of risk motifs invites questions.
On timing: glycan characterization earns its value when performed early. Waiting until late-stage development to discover a risk motif means discovering it after process lock, when mitigation options have narrowed. The consensus reading of the guidelines is that critical quality attributes — including glycosylation — should be identified during development, monitored through process changes, and bridged to the clinical material. For a program entering preclinical evaluation, baseline characterization of the glycan profile is the minimum defensible position; re-verification at each significant process change is the operational standard.
Gangliosides and glycoconjugates as analytical reference points
Here lies the bottleneck few CMC teams anticipate: a risk motif is only as credible as the reference standard used to identify and quantify it. When a subcontractor reports a Neu5Gc peak, the confirmation requires running an authentic Neu5Gc glycan standard under the same conditions — without it, the assignment rests on retention-time inference, and the result becomes hard to defend in a regulatory exchange. This is also where heterogeneous results between providers find their root cause: different labs, different standards (or none), different quantification.
Reference glycans: the missing link: Without authentic reference standards, a glycan result remains a hypothesis. With them, it becomes a quantified, comparable, regulator-defensible data point — the difference between a red flag that stalls a program and a documented, managed risk.
Some standards are straightforward to source; others are genuinely rare. Gangliosides and complex glycoconjugates — sialylated structures relevant to both immunogenicity assessment and glycoengineering targets — are frequently unavailable as catalog items, and their scarcity translates directly into analytical uncertainty. Custom synthesis closes this gap: producing a specific glycan or glycoconjugate on demand, at the purity scale the method requires. This is where specialized suppliers earn their place in a development chain. ELICITYL, for instance, combines custom synthesis of glycans and glycoconjugates with reference-standard production designed to support regulatory-grade characterization. The Gangliosides family is a good illustration: structurally complex, biologically relevant, and rarely available off the shelf.
For Claire’s situation — inconsistent glycan profiles across subcontractors — the operational answer is standardization of the reference layer: identical authentic standards shared across labs, validated quantification methods, and documented traceability. That single measure typically reconciles more discrepancies than re-running samples.
Building a practical immunogenicity risk workflow
A defensible immunogenicity risk assessment is sequenced, not improvised. The following workflow reflects practices consistent with ICH S6 and Q6B logic and standard CMC development — each step carries a decision criterion.
- Screen in silico and select the cell line knowingly.Before first production, evaluate the candidate’s sequence for risk motifs and confirm the expression system. A human cell line reduces the Neu5Gc/alpha-Gal exposure; a non-human line obliges you to plan targeted testing. Decision criterion: if a non-human line is retained, Neu5Gc and alpha-Gal enter the critical quality attribute list.
- Characterize the glycan profile with authentic standards.Run released and stressed lots against reference glycans, prioritizing risk motifs. This is where ELICITYL-type reference standards and custom glycoconjugates become operational: they turn a chromatographic peak into a quantified identity. Decision criterion: any risk-motif signal is confirmed only with an authentic standard, never by inference alone.
- Quantify and set internal thresholds.Express each motif as a share of the total glycan pool, track batch-to-batch consistency, and compare against the process baseline. Decision criterion: a motif consistently present at low, stable levels with a documented rationale is manageable; an unexplained rising trend triggers investigation.
- Run ADA testing aligned with the risk profile.Design ADA assays capable of detecting anti-glycan antibodies when risk motifs are present, and interpret results in connection with the glycan data — not in isolation. Decision criterion: ADA signals without a documented glycan rationale, or glycan motifs without ADA follow-up, both leave the risk assessment incomplete.
- Mitigate and document.Options include cell-line or process adjustment, glycoengineering, or acceptance with rationale. Decision criterion: every retained option is documented with its impact on the glycan profile, so the dossier tells a continuous story from molecule to clinical risk.
Applied to the archetypal scenario: a Neu5Gc signal appears in a lot produced on a non-human line. The team confirms the identity against an authentic standard, quantifies it against the pool, reviews whether ADA assays can detect anti-Neu5Gc antibodies, and documents the risk rationale — from motif to mitigation — before the next regulatory interaction. That sequence is what turns an alarming analytical result into a managed development topic.
Key takeaways and FAQ
- The glycosylation profile is a direct determinant of immunogenicity: non-human motifs such as Neu5Gc and alpha-Gal are documented ADA triggers, not cosmetic analytical details.
- Fc glycosylation cuts both ways: fucosylation modulates ADCC, so the same parameter can be a risk to document or a glycoengineering asset — intent must be stated early.
- ICH Q6B and ICH S6(R1) frame glycan characterization and immunogenicity evaluation; ANSM’s biosimilars work confirms the glycosylation profile as a recognized immunogenicity-shifting parameter.
- Reference glycans and glycoconjugates are the missing link: without them, risk motifs cannot be quantified or defended.
Can glycosylation be engineered to lower immunogenicity?
Yes — with nuance. Glycoengineering is a recognized lever: reshaping the glycan profile can remove risk motifs or tune Fc-mediated functions, and the ANSM explicitly cites glycosylation modifications among the parameters that can lower immunogenicity. The documented human evidence concerns mostly xenoantigen avoidance; each engineering choice still requires its own analytical and immunological documentation. Glycoengineering changes the risk profile; it does not exempt the molecule from characterization.
When should glycan characterization be performed in development?
As early as cell-line selection and first process runs. Baseline characterization of the glycosylation profile during preclinical development establishes the reference against which all later comparability is judged, and discovering a risk motif before process lock preserves mitigation options. Re-characterization at each significant process change is the operational standard.
How do we reconcile inconsistent glycan results between subcontractors?
The most frequent root cause is the reference layer: different labs using different standards — or none — produce different quantifications. Sharing identical authentic glycan reference standards across providers and validating the quantification method once, centrally, resolves most discrepancies faster than re-running samples.
This article provides general scientific and regulatory orientation for professional CMC audiences. It does not replace program-specific risk assessment, guidance interpretation or advice from qualified regulatory and toxicology professionals, and it does not constitute clinical or patient-level recommendations.
The decision that matters for a preclinical program is not whether glycans matter — they do — but whether the glycosylation profile will be characterized early enough, against reliable standards, to make every later immunogenicity claim defensible. Teams that secure this analytical foundation enter regulatory discussions with the strongest possible position: data instead of arguments. When access to specific reference glycans or custom glycoconjugates becomes the limiting step, engaging a specialized glycoscience partner such as ELICITYL is a rational next move rather than a bet.